Combined high-dose sub-tenon triamcinolone, intravitreal bevacizumab, and laser photocoagulation for refractory diabetic macular edema: a pilot study

Retina, 03/30/2012

Sustained reduction of central foveal thickness was achieved with triple therapy over the 1–year study period. Significant visual improvement was seen only in patients with worse baseline best–corrected visual acuity, but not in the triple therapy group as a whole. Significant side effects of intraocular pressure rise, ptosis, and cataractogenesis were encountered in the triple therapy group.

Print Article Summary